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Protocol
AbstrAct
Objective To study the effectiveness of four cycles of 
intrauterine insemination (IUI) with ovarian stimulation (OS) 
by follicle-stimulating hormone (FSH) or by clomiphene 
citrate (CC), and adherence to strict cancellation criteria.
Setting Randomised controlled trial among 22 secondary 
and tertiary fertility clinics in the Netherlands.
Participants 732 women from couples diagnosed with 
unexplained or mild male subfertility and an unfavourable 
prognosis according to the model of Hunault of natural 
conception.
Interventions Four cycles of IUI–OS within a time horizon 
of 6 months comparing FSH 75 IU with CC 100 mg. 
The primary outcome is ongoing pregnancy conceived 
within 6 months after randomisation, defined as a 
positive heartbeat at 12 weeks of gestation. Secondary 
outcomes are cancellation rates, number of cycles with 
a monofollicular or with multifollicular growth, number of 
follicles >14 mm at the time of ovulation triggering, time 
to ongoing pregnancy, clinical pregnancy, miscarriage, 
live birth and multiple pregnancy. We will also assess 
if biomarkers such as female age, body mass index, 
smoking status, antral follicle count and endometrial 
aspect and thickness can be used as treatment selection 
markers.
Ethics and dissemination The study has been approved 
by the Medical Ethical Committee of the Academic Medical 
Centre and from the Dutch Central Committee on Research 
involving Human Subjects (CCMO NL 43131-018-13). 
Results will be disseminated through peer-reviewed 
publications and presentations at international scientific 
meetings.
Trial registration number NTR4057.
Background
More than 70 million couples worldwide fail 
to conceive within 1 year of regular unpro-
tected intercourse.1 At present, the first-line 
treatment for couples diagnosed with unex-
plained or mild male factor subfertility is 
intrauterine insemination (IUI) with ovarian 
stimulation (OS).2 OS aims to increase the 
number of dominant follicles per cycle, based 
on the concept that this will increase preg-
nancy rates.3
OS in the context of IUI for unexplained 
subfertility or mild male subfertility can be 
achieved with follicle-stimulating hormone 
(FSH) or with clomiphene citrate (CC). 
FSH is administered as a subcutaneous 
injection from cycle day 3, 4 or 5 until the 
ovulation trigger. CC is given orally during 
5 days starting from cycle days 3 to 5. FSH 
appears to be the most effective regimen 
compared with CC in terms of pregnancy rate 
per couple.4 5 Pooling the results of seven 
randomised controlled trials (RCTs) among 
556 patients, a Cochrane review found signifi-
cantly increased pregnancy rates per couple 
in IUI–OS with FSH compared with IUI–OS 
with CC. The pregnancy rate per couple was 
28% when using FSH and 19% when using 
CC (OR 1.8, 95% CI 1.2 to 2.7).4 On the basis 
of these results, the authors recommended 
FSH in IUI–OS.4 This advice overlooks the 
high multiple pregnancy rate of around 32% 
per conception cycle after FSH versus 8% per 
Strengths and limitations of this study
 ► This is a multicentre randomised controlled trial.
 ► We aim to give cumulative pregnancy rates.
 ► This is an open-label study, which can be a limitation
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conception cycle after CC.3–5 Multiple pregnancies are 
associated with an increased risk of serious neonatal and 
maternal morbidity.6
To reduce this risk, IUI–OS with strict cancellation 
criteria, that is, when more than three dominant follicles 
develop, has been suggested. An earlier study comparing 
IUI with FSH and strict cancellation criteria to IUI with 
CC showed a multiple pregnancy rate of 6% for similar 
cumulative ongoing pregnancy and live birth rates.7 Since 
this study was underpowered and the actual number of 
follicles at ovulation triggering was not reported, there is 
still no robust evidence on the effectiveness and safety of 
this strategy in IUI.
We propose to compare in a randomised, superiority 
trial the costs and effectiveness of IUI–FSH 75 IU and IUI–
CC 100 mg and adherence to strict cancellation criteria. 
We will collect information on total number of follicles at 
ovulation triggering, cancellation rate and on biomarkers 
such as female age, body mass index (BMI), smoking 
status, antral follicle count (AFC) and endometrial aspect 
and thickness to identify any treatment selection markers 
to open up the possibility of a personalised approach.
oBjecTive
To study the effectiveness of four cycles of IUI–FSH 75 IU 
compared with IUI–CC 100 mg, and adherence to strict 
cancellation criteria, that is, when more than three domi-
nant follicles develop.
MeThods
study design
This study is a non-blinded, multicentre, superiority RCT 
in the Netherlands. Recruitment started on 5 June 2013. 
We expect to end the study on 1 August 2017. Trial regis-
tration number is NTR4057.
study population
Inclusion criteria
We will study couples diagnosed with unexplained or 
mild male subfertility, in whom the woman is between 18 
and 43 years and with at least one-sided tubal patency.
Unexplained subfertility is defined as a couple having 1 
year of regular unprotected intercourse without concep-
tion, where the woman has a regular menstrual cycle and 
the man a prewash total motile sperm count (TMSC) of 
above 10 million.
Mild male subfertility is defined as prewash TMSC 
above 3 million and less than 10 million.
The following couples are eligible:
 ► Couples in whom the woman is under the age 
of 38 years with 12 months prognosis for natural 
conception according to the model of Hunault 
of <30%. This model encompasses female age, 
duration of subfertility, whether subfertility is primary 
or secondary, percentage of motile progressive 
sperm and referral status. It is readily available for 
all clinicians.8
 ► Couples in whom the woman is under the age 
of 38 years with 12 months prognosis for natural 
conception according to the model of Hunault 
of >30% after another 6 months of failed expectant 
management.
 ► Couples in whom the woman is at the age of 38 years 
or older regardless of their 12 months prognosis for 
natural conception.
 ► Women under the age of 35 years after 12 months of 
intracervical insemination (ICI) or IUI with donor 
sperm without OS.
 ► Women 35 years or older after 6 months of ICI or 
IUI with donor sperm without OS.
exclusion criteria
Women with double-sided tubal pathology, polycystic 
ovary syndrome, irregular cycles or other endocrine 
disorders are not included.
ethical considerations
Approval for this study is obtained from the Medical 
Ethical Committee of the Academic Medical Centre and 
from the Dutch Central Committee on Research involving 
Human Subjects (CCMO NL 43131-018-13). Before 
randomisation, written informed consent was obtained in 
patients fulfilling the inclusion criteria.
informed consent procedure
Women eligible for participation in the study are invited 
for additional counselling by a research nurse to ensure 
that they are fully informed on the nature of the study by 
means of both oral and written information. Women who 
agree to participate are asked to sign a written informed 
consent of which they receive a copy.
randomisation
Randomisation is performed by accessing a web-based 
data system that is used for randomisation in clinical trials 
and will be performed centrally with the use of a permut-
ed-block design. Couples are randomly allocated to either 
four cycles of IUI with subcutaneous injections of FSH at 
a dose of 75 IU or with CC tablets at a dose of 100 mg.
interventions
Couples are treated until pregnancy occurs within a treat-
ment time horizon of 6 months (figure 1).
In the first treatment cycle, all women are seen for a 
baseline visit with a transvaginal ultrasound on the third, 
fourth or fifth day of the menstrual cycle. At this baseline 
visit, the AFC will be measured.
Women are not allowed to start the treatment cycle if 
one or more ovarian cysts of >20 mm are seen, but may 
continue as soon as the cysts have disappeared.
In the experimental arm, women will receive IUI–FSH. 
The recruited women start with daily subcutaneous injec-
tions of 75 IU FSH on day 3, 4 or 5 of the menstrual cycle 
and continue these injections until the day of ovulation 
triggering. In the standard arm, women start with 100 mg 
CC on day 3, 4 or 5 of the menstrual cycle. The tablets 
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are administered orally and stopped after 5 days of daily 
intake.
Growing follicles are monitored by transvaginal ultra-
sound and the subsequent insemination is planned if 
there is at least one dominant follicle with a mean diam-
eter of 16–18 mm and a maximum of three follicles of 
15 mm. Ovulation is triggered with 5000 IU hCG or 250 
µg recombinant hCG.
In both interventions, the total number of follicles, 
their diameters and the endometrial aspect and thickness 
are measured at the final ultrasound before ovulation trig-
gering and registered. Ovulation triggering is withheld if 
more than three follicles with a diameter of >15 mm are 
seen or five follicles with a diameter of 12 mm. In this case, 
the couples are also strictly advised to have protected or 
no intercourse. IUI is scheduled 36–42 hours after ovula-
tion triggering. On the day of insemination, the partner 
Figure 1 Flowchart of study. CC, clomiphene citrate; FSH, follicle-stimulating hormone; ICI, intracervical insemination; IUI, 
intrauterine insemination; OS, ovarian stimulation; TMSC, total motile sperm count.
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will provide a semen sample after a minimum of 2 days 
of sexual abstinence. The semen is processed according 
to local protocol. In case of donor sperm treatment, 
donor semen is thawed and processed according to local 
protocol.
Women who are not pregnant are scheduled for 
the next insemination cycle. In case of monofollicular 
growth or cancellation of the cycle because of the growth 
of more than three follicles above 14 mm, the dose is 
adjusted in the subsequent cycle. It is known that IUI 
with monofollicular growth does not contribute to preg-
nancy outcomes compared with expectant management 
(9). If monofollicular development occurred, the dose of 
recombinant FSH was increased by 37.5 IU, and in case 
of CC, the dose was increased by 50 mg in the next cycle. 
If a cycle was cancelled due to multifollicular growth, the 
dose of rFSH was decreased by 37.5 IU, and in case of CC, 
the dose was decreased by 50 mg in the next cycle.
ouTcoMe Measures
Primary outcome measure
The primary outcome is conception leading to ongoing 
pregnancy, defined as a positive heartbeat at 12 weeks of 
gestation. Only conceptions that occur within the first 6 
months after randomisation will count for the assessment 
of the primary endpoint.
secondary outcome measure
Secondary outcomes are cancellation rates, number of 
cycles with a monofollicular and multifollicular growth, 
total number of follicles >14 mm at the time of ovulation 
triggering, time to ongoing pregnancy, clinical pregnancy 
rate, miscarriage rate, live birth rate and multiple preg-
nancy rate. We will also assess patients’ preference and 
costs. We will collect information on biomarkers such as 
female age, duration and type of subfertility, TMSC, 
Hunault score, BMI, smoking status, ethnicity and AFC 
and endometrial aspect and thickness.
Background and demographic characteristics
We will present the baseline measurements including 
female age, duration of subfertility, diagnosis of subfer-
tility, parity, semen quality and referral status.
data analysis
On the basis of a superiority design, the analysis of all 
outcomes will be done on an intention-to-treat basis.
Baseline data and outcome data are summarised 
separately. For continuous variables, we examine the 
distribution of the observations, and if normally distrib-
uted, we summarise them as means with SDs. If they are 
not normally distributed, medians and IQRs are reported. 
For dichotomous data, we provide proportions (or 
percentages). In addition to the baseline and outcome 
data, we also summarise the recruitment numbers, those 
lost to follow-up, protocol violations and other relevant 
data.
We will analyse a maximum of four cycles of IUI–OS 
performed within a time horizon of 6 months after rando-
misation.
The effectiveness of IUI–FSH versus IUI–CC is expressed 
as a rate ratio for ongoing pregnancy with corresponding 
95% CIs. A formal test of the difference in ongoing preg-
nancy rate will be performed using χ2 test statistics.
The effectiveness over time is evaluated in life tables and 
differences in ongoing pregnancy over time are evaluated 
by the log-rank test. Further dichotomous outcomes are 
analysed using the Fishers exact test or χ2 test as appro-
priate. For continuous outcomes, we use t-test if the 
observations in each trial arm are normally distributed, 
and if non-normally distributed, then Mann-Whitney U 
test is used. Although p values are reported, the focus is 
on providing 95% CIs around point estimates, as these 
are more useful in interpreting the findings of the trial.
If randomisation fails to achieve balanced groups, we 
will perform secondary analyses in which we adjust for 
unbalanced prognostic factors using procedures such as 
logistic regression. If the primary unadjusted analysis and 
secondary adjusted analysis are discordant, we will give 
greater weighting to the primary analysis in the interpre-
tation of trial findings.
For issues such as loss to follow-up, missing data and 
protocol violations, we attempt sensitivity (‘worst-case 
scenario’) analyses to explore the effect of these factors 
on the trial findings. The effect of baseline characteris-
tics on the primary outcome is explored using logistic 
regression analysis. We will construct Kaplan-Meier curves 
expressing time to ongoing pregnancy.
Biomarker study
We will classify female age, BMI, duration of subfertility, 
TMSC and Hunault score as continuous variables and 
endometrial thickness at start cycle, type of subfertility 
(primary or secondary) and smoking status (yes or no) 
as binary variables. For each potential treatment selec-
tion marker, we will explore the association between the 
factor and ongoing pregnancy after IUI–FSH and IUI–CC 
and will test for factor–treatment interaction. For contin-
uous factors, we will plot ongoing pregnancy chance as 
a function of the prognostic factor in a Subpopulation 
Treatment Effect Pattern Plot (STEPP).10 11 STEPP is a 
non-parametric approach allowing for investigation of 
patterns of treatment effect heterogeneity in subgroups 
of the factor that is being studied. For binary factors, we 
will develop logistic regression models and calculate the 
p value of factor–treatment interaction. In a sensitivity 
analysis, we will also perform the same analyses using 
ongoing pregnancy rate as main effectiveness outcome.
Given the exploratory nature of our analysis, we will 
use a more liberal p value of 0.1.12 All analyses will be 
performed based on the intention-to-treat principle. We 
will use R for Windows (Version 3.0.1; R Foundation for 
Statistical Computing, Vienna, Austria); STEPP analyses 
will be done by package ‘stepp’ (https:// cran. r- project. 
org/ web/ packages/ stepp/ stepp. pdf) and evaluation of 
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the performance of binary factors by the package ‘Treat-
ment Selection’.13
economic evaluation
We will perform an economic analysis from a healthcare 
perspective alongside the clinical trial. We make a distinc-
tion between direct costs (costs like medical interventions 
and other healthcare costs like medical appliances) and 
indirect costs (costs of productivity loss or time loss costs). 
We analyse a cost-minimization or cost-effectiveness anal-
ysis depending on the outcome of ongoing pregnancy 
rates in both groups. We present the cost-effectiveness 
of each strategy as cost per ongoing pregnancy and 
costs per live birth. We explore the robustness of the 
results for various assumptions and parameter estimates 
in sensitivity analysis outcomes and we express these in 
incremental cost-effectiveness ratio graphs and cost-effec-
tiveness acceptability curves. The economic evaluation 
will be reported in a separate paper.
Power calculation
The study is designed as a superiority trial. We assume 
that the ongoing pregnancy rate after four cycles will be 
25% following CC treatment and we aim to be able to 
prove an absolute difference of 10% following FSH.14 
With a two-sided alpha of 5% and a beta of 20%, 329 
couples per group are required. Accounting for 10% 
dropout extra, we need to include 732 women.
discussion
In couples diagnosed with unexplained or mild male 
subfertility, the first-line treatment is IUI with OS. OS can 
be achieved with FSH or CC. On the basis of the available 
evidence, FSH appears to be the most effective medication 
in terms of the pregnancy rate per couple compared with 
CC. The disadvantage is the risk of multiple pregnancies 
and its associated maternal and neonatal complications. 
A way to reduce the risk of multiple pregnancies is to hold 
on to strict cancellation criteria. A cycle will be cancelled 
when three or more dominant follicles develop. Within 
this strategy, it is unclear whether OS should be done with 
FSH or with CC. The objective of this multicentre RCT is 
to determine the costs and effectiveness of IUI–FSH 75 IU 
and IUI–CC 100 mg, and adherence to strict cancellation 
criteria.
eThics and disseMinaTion
The study has been approved by the Medical Ethical 
Committee of the Academic Medical Centre and from 
the Dutch Central Committee on Research involving 
Human Subjects (CCMO NL 43131-018-13). Results will 
be disseminated through peer-reviewed publications and 
presentations at international scientific meetings.
Author affiliations
1Center for Reproductive Medicine, Academic Medical Center, Amsterdam, The 
Netherlands
2Obstetrics and gynaecology, Maxima Medical Center, Veldhoven, The Netherlands
3Kennemer Hospital, Haarlem, The Netherlands
4Jeroen Bosch Hospital, Den Bosch, The Netherlands
5Isala Zwolle, Zwolle, The Netherlands
6Martini Hospital, Groningen, The Netherlands
7Leiden University Medical Centre, Leiden, The Netherlands
8Sint Franciscus Gasthuis, Rotterdam, The Netherlands
9Reproductive Medicine, UMC Utrecht, Utrecht, The Netherlands
10Radboud University Medical Centre, Nijmegen, The Netherlands
11Groene Hart Hospital, Gouda, The Netherlands
12NoordWest Groep Alkmaar, Alkmaar, The Netherlands
13St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
14MC Zuiderzee, Lelystad, The Netherlands
15Gelre Hospital, Apeldoorn, The Netherlands
16Fertility Clinic Twente, Twente, The Netherlands
17Scheper Hospital, Emmen, The Netherlands
18Amphia, Breda, The Netherlands
19Medical Centre Leeuwarden, Leeuwarden, The Netherlands
20Spaarne Hospital, Hoofddorp, The Netherlands
21OLVG, Amsterdam, The Netherlands
22Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
23The Robinson Institute, School of Paediatrics and Reproductive Health, University 
of Adelade, Adelaide, Australia
Acknowledgements This trial received funding from the Dutch Organisation for 
Health Research and Development (ZonMw, http://www. zonmw. nl/ nl/).%20There is 
no role in the study for ZonMW.
Contributors ND is responsible for the overall logistical aspects of the trial and 
drafted the paper. MHM, FvdV and MvW designed the trial and were responsible 
for the development of the protocol. ND, CK, JG, JPdB, BJC, DPvdH, NFK, MHAvH, 
FB, KF, CAHJ, JMRvW, JvD, M Twisk, M Traas, MFGV, MJP, JV, DAMP, DESB, HRV, 
CFvH, BWJM, SR, MHM and MvW contributed to the protocol included patients and 
approved the final version of the paper.
Competing interests None declared.
Ethics approval Approved by METC AMC Amsterdam.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1. Boivin J, Bunting L, Collins JA, et al. International estimates of 
infertility prevalence and treatment-seeking: potential need and 
demand for infertility medical care. Hum Reprod 2007;22:1506–12.
 2. Verhulst SM, Cohlen BJ, Hughes E, et al. Intra-uterine insemination 
for unexplained subfertility. Cochrane Database Syst Rev 
2006:CD001838.
 3 van Rumste MM, Custers IM, van der Veen F, et al. The influence 
of the number of follicles on pregnancy rates in intrauterine 
insemination with ovarian stimulation: a meta-analysis. Hum Reprod 
Update. 2008;14:563–70.
 4. Cantineau AEP, Cohlen BJ. Ovarian stimulation protocols anti-
oestrogens, gonadotrophins with and without GnRH agonists/
antagonists) for intrauterine insemination (IUI) in women with 
subfertility. Cochrane Database Syst Rev 2009.
 5. Diamond MP, Richar SL, Coutifaris C, et al. Letrozole, gonadotropin, 
or clomiphene for unexplained infertility. N Engl J Med 2015:373.
 6. Ombelet W, Martens G, De Sutter P, et al. Perinatal outcome of 
12,021 singleton and 3108 twin births after non-IVF-assisted 
reproduction: a cohort study. Hum Reprod 2006;21:4.
 7. Dankert T, Kremer JA, Cohlen BJ, et al. A randomized clinical trial 
of clomiphene citrate versus low dose recombinant FSH for ovarian 
hyperstimulation in intrauterine insemination cycles for unexplained 
and male subfertility. Hum Reprod 2007;22.
group.bmj.com on July 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Danhof NA, et al. BMJ Open 2017;7:e015680. doi:10.1136/bmjopen-2016-015680
Open Access 
 8. vdS JW. Pregnancy is predictable: a large-scale prospective external 
validation of the prediction of spontaneous pregnancy in subfertile 
couples. Human Rep 2007;22:563–42.
 9 Veltman-Verhulst SM, Hughes E, Ayeleke RO, et al. Intra-uterine 
insemination for unexplained subfertility. Cochrane Database Syst 
Rev 2016;2:CD001838.
 10 Lazar AA, Bonetti M, Cole BF, et al. Identifying treatment effect 
heterogeneity in clinical trials using subpopulations of events: stepp. 
Clin Trials 2016;13:169–79.
 11 Selvin S. Statistical analysis of epidemiologic data. New York: Oxford 
University Press, 1996.
 12 Bonetti M, Gelber RD. Patterns of treatment effects in subsets of 
patients in clinical trials. Biostatistics  
2004;5:465–81.
 13 Janes H, Brown MD, Huang Y, et al. An approach to evaluating and 
comparing biomarkers for patient treatment selection. Int J Biostat 
2014;10.
 14 Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PM, et al. Prevention of 
multiple pregnancies in couples with unexplained or mild male 
subfertility: randomised controlled trial of in vitro fertilisation with 
single embryo transfer or in vitro fertilisation in modified natural cycle 
compared with intrauterine insemination with controlled ovarian 
hyperstimulation. Bmj 2015;350:g7771.
 15 Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation 
and elaboration: guidance for protocols of clinical trials. BMJ 
2013;346:e7586.
 16. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
group.bmj.com on July 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
stimulation in intrauterine insemination
hormone and clomiphene citrate for ovarian
controlled trial comparing follicle-stimulating 
The SUPER study: protocol for a randomised
and MH Mochtar
HR Verhoeve, CF van Heteren, BWJ Mol, S Repping, F van der Veen
M Traas, MFG Verberg, MJ Pelinck, J Visser, DAM Perquin, DES Boks, 
Fleischer, CAH Janssen, JM Rijn van Weert, J van Disseldorp, M Twisk,
Cohlen, DP van der Ham, NF Klijn, MHA van Hooff, FJM Broekmans, K 
NA Danhof, M van Wely, CAM Koks, J Gianotten, JP de Bruin, BJ
doi: 10.1136/bmjopen-2016-015680
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/5/e015680
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/7/5/e015680
This article cites 10 articles, 5 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (46)Reproductive medicine
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
